12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CG0070: SPA received

Cold Genesys said it reached an agreement with FDA on an SPA for the open-label Phase II/III BOND trial to compare intravesical CG0070 administered weekly for 6 weeks vs. the active comparator mitomycin C, interferon, valrubicin or gemcitabine in 210 patients. The trial will enroll patients with non-invasive bladder cancer with...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >